1-20 of 23
protein-tyrosine kinase inhibitor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis

David J. Young, Bao Nguyen, Ruiqi Zhu, Jaesung Seo, Li Li, Mark J. Levis, Keith W. Pratz, Amy S. Duffield, Donald Small
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2285–2293.
https://doi.org/10.1182/bloodadvances.2020002876
Published: 2021
Includes: Supplemental data
Journal Articles

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Chaja F. Jacobs, Eric Eldering, Arnon P. Kater
Journal: Blood Advances
Blood Adv (2021) 5 (3): 913–925.
https://doi.org/10.1182/bloodadvances.2020003768
Published: 2021
Includes: Supplemental data
Journal Articles

Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission

Clinical Trials & Observations
Philippe Rousselot, Clémence Loiseau, Marc Delord, Jean Michel Cayuela, Marc Spentchian
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3034–3040.
https://doi.org/10.1182/bloodadvances.2020001772
Published: 2020
Includes: Supplemental data
Journal Articles

First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis

Clinical Trials & Observations
Claudia Vener, Rita Banzi, Federico Ambrogi, Annalisa Ferrero, Giuseppe Saglio, Gabriella Pravettoni, Milena Sant
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2723–2735.
https://doi.org/10.1182/bloodadvances.2019001329
Published: 2020
Includes: Supplemental data
Journal Articles

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

Clinical Trials & Observations
Catherine C. Smith, Mark J. Levis, Olga Frankfurt, John M. Pagel, Gail J. Roboz, Richard M. Stone, Eunice S. Wang, Paul L. Severson, Brian L. West, Mai H. Le, Sabine Kayser, Bao Lam, Henry H. Hsu, Chao Zhang, Gideon Bollag, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1711–1721.
https://doi.org/10.1182/bloodadvances.2020001449
Published: 2020
Includes: Supplemental data
Journal Articles

Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia

Clinical Trials & Observations
Richard C. Harvey, Sarah K. Tasian
Journal: Blood Advances
Blood Adv (2020) 4 (1): 218–228.
https://doi.org/10.1182/bloodadvances.2019000163
Published: 2020
Journal Articles

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

Clinical Trials & Observations
Michele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso, Francesco Albano, Mario Annunziata, Sara Barulli, Germana Beltrami, Micaela Bergamaschi, Gianni Binotto, Monica Bocchia, Giovanni Caocci, Isabella Capodanno, Francesco Cavazzini, Michele Cedrone, Marco Cerrano, Monica Crugnola, Mariella D’Adda, Chiara Elena, Carmen Fava, Paola Fazi, Claudio Fozza, Sara Galimberti, Valentina Giai, Antonella Gozzini, Gabriele Gugliotta, Alessandra Iurlo, Gaetano La Barba, Luciano Levato, Alessandro Lucchesi, Luigia Luciano, Francesca Lunghi, Monia Lunghi, Michele Malagola, Roberto Marasca, Bruno Martino, Angela Melpignano, Maria Cristina Miggiano, Enrico Montefusco, Caterina Musolino, Fausto Palmieri, Patrizia Pregno, Davide Rapezzi, Giovanna Rege-Cambrin, Serena Rupoli, Marzia Salvucci, Rosaria Sancetta, Simona Sica, Raffaele Spadano, Fabio Stagno, Mario Tiribelli, Simona Tomassetti, Elena Trabacchi, Massimiliano Bonifacio, Massimo Breccia, Fausto Castagnetti, Fabrizio Pane, Domenico Russo, Giuseppe Saglio, Simona Soverini, Paolo Vigneri, Gianantonio Rosti
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4280–4290.
https://doi.org/10.1182/bloodadvances.2019000865
Published: 2019
Journal Articles

LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML

Neil Beeharry, Sean Landrette, Sophia Gayle, Marylens Hernandez, Jeff E. Grotzke, Peter R. Young, Paul Beckett, Xuan Zhang, Bing Z. Carter, Michael Andreeff, Stephanie Halene, Tian Xu, Jonathan Rothberg, Henri Lichenstein
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3661–3673.
https://doi.org/10.1182/bloodadvances.2019001068
Published: 2019
Includes: Supplemental data
Journal Articles

Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation

Clinical Trials & Observations
Chihiro Yamamoto, Hirotomo Nakashima, Takashi Ikeda, Shin-ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Kiyomi Mashima, Takashi Nagayama, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Miyuki Sugimoto, Yuko Ishihara, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Shin-ichiro Fujiwara, Masuzu Ueda, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3266–3277.
https://doi.org/10.1182/bloodadvances.2019000745
Published: 2019
Includes: Supplemental data
Journal Articles

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia

Clinical Trials & Observations
Adrian G. Minson, Katherine Cummins, Lucy Fox, Ben Costello, David Yeung, Rebecca Cleary, Cecily Forsyth, Maciek Tatarczuch, Kate Burbury, Olga Motorna, Jake Shortt, Shaun Fleming, Andrew McQuillan, Anthony Schwarer, Rosemary Harrup, Amy Holmes, Sumita Ratnasingam, Kah-Lok Chan, Wei-Hsun Hsu, Asma Ashraf, Faye Putt, Andrew Grigg
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1084–1091.
https://doi.org/10.1182/bloodadvances.2018028035
Published: 2019
Includes: Supplemental data
Journal Articles

Role of CYP3A4 in bone marrow microenvironment–mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors

Yu-Ting Chang, Daniela Hernandez, Salvador Alonso, Minling Gao, Meng Su, Gabriel Ghiaur, Mark J. Levis, Richard J. Jones
Journal: Blood Advances
Blood Adv (2019) 3 (6): 908–916.
https://doi.org/10.1182/bloodadvances.2018022921
Published: 2019
Includes: Supplemental data
Journal Articles

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Clinical Trials & Observations
Preetesh Jain, Hagop Kantarjian, Prajwal C. Boddu, Graciela M. Nogueras-González, Srdan Verstovsek, Guillermo Garcia-Manero, Gautam Borthakur, Koji Sasaki, Tapan M. Kadia, Princy Sam, Hycienth Ahaneku, Susan O’Brien, Zeev Estrov, Farhad Ravandi, Elias Jabbour, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2019) 3 (6): 851–861.
https://doi.org/10.1182/bloodadvances.2018025874
Published: 2019
Includes: Supplemental data
Journal Articles

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI

Clinical Trials & Observations
Naranie Shanmuganathan, Susan Branford, Timothy P. Hughes, Devendra Hiwase
Journal: Blood Advances
Blood Adv (2019) 3 (3): 370–374.
https://doi.org/10.1182/bloodadvances.2018027516
Published: 2019
Includes: Supplemental data
Journal Articles

A second-generation TKI should always be used as initial therapy for CML

Clinical Trials & Observations
Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3653–3655.
https://doi.org/10.1182/bloodadvances.2018018655
Published: 2018
Journal Articles

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia

Saurabh Chhabra, Kwang Woo Ahn, Zhen-Huan Hu, Sandeep Jain, Amer Assal, Jan Cerny, Edward A. Copelan, Andrew Daly, Zachariah DeFilipp, Shahinaz M. Gadalla, Robert Peter Gale, Siddhartha Ganguly, Betty K. Hamilton, Gerhard Carl Hildebrandt, Jack W. Hsu, Yoshihiro Inamoto, Abraham S. Kanate, H. Jean Khoury, Hillard M. Lazarus, Mark R. Litzow, Sunita Nathan, Richard F. Olsson, Attaphol Pawarode, Olle Ringden, Jacob M. Rowe, Ayman Saad, Bipin N. Savani, Harry C. Schouten, Sachiko Seo, Nirav N. Shah, Melhem Solh, Robert K. Stuart, Celalettin Ustun, Ann E. Woolfrey, Jean A. Yared, Edwin P. Alyea, Matt E. Kalaycio, Uday Popat, Ronald M. Sobecks, Wael Saber
Journal: Blood Advances
Blood Adv (2018) 2 (21): 2922–2936.
https://doi.org/10.1182/bloodadvances.2018024844
Published: 2018
Includes: Supplemental data
Journal Articles

Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL

Clinical Trials & Observations
Ina-Katrin Siekmann, Kevin Dierck, Sebastian Prall, Marianne Klokow, Julia Strauss, Sophia Buhs, Antonina Wrzeszcz, Michael Bockmayr, Florian Beck, Magdalena Trochimiuk, Kristina Gottschling, Victoria Martens, Melissa Khosh-Naucke, Helwe Gerull, Jürgen Müller, Lena Behrmann, Martin Blohm, René P. Zahedi, Irmela Jeremias, Albert Sickmann, Peter Nollau, Martin A. Horstmann
Journal: Blood Advances
Blood Adv (2018) 2 (19): 2554–2567.
https://doi.org/10.1182/bloodadvances.2018020693
Published: 2018
Includes: Supplemental data
Journal Articles

A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML

Srila Gopal, Qing Lu, Joshua J. Man, Wendy Baur, Sitara P. Rao, Lev Litichevskiy, Malvina Papanastasiou, Amanda L. Creech, Katherine C. DeRuff, James Mullahoo, Adam Officer, Shawn B. Egri, Desiree Davison, Jacob D. Jaffe, Iris Z. Jaffe
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1680–1684.
https://doi.org/10.1182/bloodadvances.2018020396
Published: 2018
Includes: Supplemental data
Journal Articles

Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia

Anne-Sophie Bouillon, Monica S. Ventura Ferreira, Shady Adnan Awad, Johan Richter, Andreas Hochhaus, Volker Kunzmann, Jolanta Dengler, Jeroen Janssen, Gert Ossenkoppele, Peter E. Westerweel, Peter A. W. te Boekhorst, Francois-Xavier Mahon, Henrik Hjorth-Hansen, Susanne Isfort, Thoas Fioretos, Sebastian Hummel, Mirle Schemionek, Stefan Wilop, Steffen Koschmieder, Susanne Saußele, Satu Mustjoki, Fabian Beier, Tim H. Brümmendorf
Journal: Blood Advances
Blood Adv (2018) 2 (13): 1572–1579.
https://doi.org/10.1182/bloodadvances.2018017772
Published: 2018
Includes: Supplemental data
Journal Articles

In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1 + BCP-ALL

Eleanor R. C. Fiedler, Arjun Bhutkar, Emily Lawler, Rana Besada, Michael T. Hemann
Journal: Blood Advances
Blood Adv (2018) 2 (11): 1229–1242.
https://doi.org/10.1182/bloodadvances.2017015610
Published: 2018
Includes: Supplemental data
Journal Articles

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia

Clinical Trials & Observations
Thai Hoa Tran, Marian H. Harris, Jonathan V. Nguyen, Traci M. Blonquist, Kristen E. Stevenson, Eileen Stonerock, Barbara L. Asselin, Uma H. Athale, Luis A. Clavell, Peter D. Cole, Kara M. Kelly, Caroline Laverdiere, Jean-Marie Leclerc, Bruno Michon, Marshall A. Schorin, Jennifer J. G. Welch, Shalini C. Reshmi, Donna S. Neuberg, Stephen E. Sallan, Mignon L. Loh, Lewis B. Silverman
Journal: Blood Advances
Blood Adv (2018) 2 (5): 529–533.
https://doi.org/10.1182/bloodadvances.2017014704
Published: 2018